A Prospective Cohort of Children With HIV Infection

The HIV Netherlands Australia Thailand Research Collaboration

Status: Completed

Conditions: HIV Infections

Treatments: Drug: Zidovudine, Stavudine, Didanosine, Lamivudine; Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir; Drug: Nevirapine, Efavirenz

Study type: Observational

Funder types: Other

Identifiers

NCT00476606

HIV-NAT 015

Details and patient eligibility

About

To evaluate clinical and immunological outcome of children treated with HAART.

Full description

This is a long term cohort study that was started in 2002. Currently, there are 120 children enrolled in the study and are receiving HIV care according to standard practice set by the Thai Ministry of Public Health. HIV-infected parents also receive care at the same clinic.

Enrollment: 500 patients

Sex: All

Ages: 1 day to 20 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center
• Children who fulfil criteria to start HAART according to the ATC program
• Children who are switched to second regimen or salvage therapy
• Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)
• Children with HIV infection who are not on antiretroviral therapy
• Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form

Exclusion criteria

• Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.

Trial design

500 participants in 1 patient group

Long-term pediatric cohort

Description:

Long-term follow-up cohort since 2003

Treatment:

Drug: Nevirapine, Efavirenz

Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir

Drug: Zidovudine, Stavudine, Didanosine, Lamivudine